Mehdi Hamadani, MD: In My Experience Question 6
COVID-19 and Cancer CareAre you proceeding with front-line autologous transplant in patients with mantle cell lymphoma or delaying it during the COVID-19 pandemic?
Recorded April 21, 2020.
Related Videos
Paolo A. Ascierto, MD, on Cancer Treatment During the COVID-19 Pandemic: The View From Southern Italy
Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori in Naples, Italy, talks about minimizing risks for patients with cancer, prioritizing surgery and other treatments for...
William A. Wood, MD, MPH, on the New ASH Research Collaborative Data Hub COVID-19 Registry for Hematologic Malignancy
William A. Wood, MD, MPH, of the University of North Carolina at Chapel Hill, and Oversight Group Chair for the new COVID-19 registry, talks about why it was formed, how it c...
Mikkael A. Sekeres, MD, on Cancer Treatment in the Age of COVID-19: Personal Observations
Mikkael A. Sekeres, MD, of the Cleveland Clinic, talks about the ways in which social distancing and viral fears have affected the way he delivers treatment for his patients,...
Irene M. Ghobrial, MD, on How COVID-19 is Changing the Conduct of Clinical Trials
Irene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma...
Saad Z. Usmani, MD: In My Experience Question 1
As a result of COVID-19, has your decision model for front-line therapy changed for patients with multiple myeloma who are either transplant-eligible or ineligible? ...
